The Clinical Spectrum and Neurodevelopmental Pathogenesis of KPTN-Related Disorder in a Mouse Model

作者信息Lettie E Rawlins, Philip H Iffland 2nd, John Page, Rebecca Z Flessner, Soad M Elziny, Irina Sbornova, Janice K Babus, Sophie R Bruckmeier, Ria Parikh, Merel Verhoeven, James Fasham, Joseph S Leslie, Richard Caswell, Nishanka Ubeyratna, Olivia Wenger, Ethan M Scott, John Schreiber, Steffen Syrbe, Annick Klabunde-Cherwon, Martina Owens, Andrew H Crosby, Emma L Baple, Peter B Crino, KPTN Consortium, Andrea Seeley, Heather Rocha, Sabine Rudnick, Ulrich Schaatz, Tobias Haack, Eva Schwaibold, Caleb Bupp, Klaas Wierenga, John Schreiber, Thorkild Terkelsen, Sarina Kant, J C Herkert, Michael Wright, Boris Keren, Solveig Heide, Pamela Jackson, Pradeep Vasudevan, Helen Stewart, Perrine Charles, Andreas Hahn, Saskia Biskup, Inger-Lise Mero, Martin Heier, Conny van Ravenswaaij-Arts, Esther Nibbeling, Stephanie Efthymiou, Erum Afzal, Ian Ellis, Raza Maroofian, Almundher Al-Maawali, David Coman, Anthony Morosini, Sajjad Biglari, Pooneh Nikuei, Saadet Mercimek-Andrews, Prab Prabhakar, Raymond Louie, Kameryn Butler, Olivia Wenger, Ethan M Scott, Andrea Seeley, Heath
PMID41696790
期刊Ann Neurol
发布时间2026-05
DOI10.1002/ana.78159

摘要

Objective: Pathogenic variants in Kaptin (KPTN) cause KPTN-related disorder (KRD). KPTN modulates mTOR signaling activation within the KICSTOR complex in response to cellular amino acid levels. We define the clinical spectrum and investigate the developmental pathogenesis of KRD. Methods: We report the genotype and clinical phenotype of 71 KRD individuals (28 female subjects, ages 1 to 55 years) including 48 newly identified KRD individuals. The effects of Kptn knockout on brain development were assayed in vitro and in vivo. Results: We defined 15 novel KPTN variants. Intellectual disability (ID) was identified in all KRD individuals. Macrocephaly and epilepsy were observed in 46% and 47%, respectively. Neuroimaging revealed megalencephaly but no overt structural abnormalities. Ketotic hypoglycemia and endocrinopathies were identified in KRD. Increased head size was detected in unaffected parents heterozygous for KPTN variants. Two KRD individuals with drug-resistant epilepsy were treated with the mTOR inhibitor sirolimus but did not exhibit improved seizure control. CRISPR/Cas9 Kptn knockout in vitro induced mTOR activation and an mTOR-dependent increase in cell size. Kptn-/- mice exhibited increased cortical mTOR signaling that was reduced by rapamycin. Heterotopic neurons were identified in the subcortical white matter in the Kptn -/- mouse. Focal CRISPR/Cas9 Kptn knockout in cortex via in utero electroporation resulted in white matter heterotopic neurons. Electroencephalogram (EEG) did not detect ictal or inter-ictal abnormalities. Interpretation: KRD is a multisystem neurodevelopmental disorder associated with ID, macrocephaly, epilepsy, mTOR signaling hyperactivation, and in a mouse model, subtle structural alterations in cerebral cortical cytoarchitecture. ANN NEUROL 2026;99:1287-1302.

实验方法

产品清单

名称品牌货号
Illumina HumanCytoSNP-12 v2.1 微珠芯片阵列IlluminaHumanCytoSNP‐12 version 2.1 beadchip array
PX458质粒Addgene#48138
Lipofectamine LTX 与 Plus 试剂ThermoFisher Scientific--
Pinnacle Technology 3通道脑电图系统Pinnacle Technology--
Seizure Pro 软件Pinnacle Technology--
GraphPad Prism 10GraphPad10